CardioMEMS™ HERO Device

The *hero* behind proven heart failure management

The HERO Device is an easy-to-use,[1] next-generation CardioMEMS reader that empowers patients to conveniently[1] take and send pulmonary artery (PA) pressure readings. It encourages a consistent reading position, which provides reliable, accurate trends to manage care.[2]

60%
lighter and smaller than the previous generation reader[1]*

Easy to carry for daily use and travel
to conveniently[1] send PA pressure readings

Intuitive interface
- Step-by-step instructions[1]

Simple set up with easy connection[1]
- Designed to help signal acquisition
- Integrated Wi-Fi

CardioMEMS™ HERO Device

Heart failure management that's proven and consistent

Patients empowered

to take readings independently[1] and send regular updates on their PA pressure.

Proven PA pressure reduction

which is linked to lower mortality[3] and fewer HF hospitalizations.[4-6]

Outcomes validated

in three Randomized Control Trials and 10+ years of experience.[4-6]

Learn more about the CardioMEMS™ HF System at

cardiovascular.abbott/cardiomems

Explore Abbott's CardioSupport Program for pre- and post-implant patient education at

cardiovascular.abbott/cardiosupport

*including travel case

1. Abbott data on file, based on internal validation studies with representative users. Results may vary.
2. Khedraki R, Abraham J, Jonsson O, et al. Impact of exercise on pulmonary artery pressure in patients with heart failure using an ambulatory pulmonary artery pressure monitor. *Front Cardiovasc Med*. 2023;10:1077365. Published 2023 Mar 2. doi:10.3389/fcvm.2023.1077365
3. Zalawadiya S, Abraham J, Rathman L, et al. Early Reduction of Pulmonary Artery Pressures Is Associated With Improved Mortality Among Medicare Beneficiaries With Heart Failure. *JACC Heart Fail*. 2025;13(10):102589. doi:10.1016/j.jchf.2025.102589
4. Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomized controlled trial. *The Lancet*. 2011;377(9766):658-66
5. Brugts JJ, Radhoe SP, Clephas PRD, et al. Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial [published correction appears in The Lancet. 2023;401(10394):2112]. *The Lancet*. 2023;401(10394):2113-2123. doi:10.1016/S0140-6736(23)00923-6
6. Lindenfeld J, Zile MR, Desai AS, et al. Haemodynamic-guided management of heart failure (GUIDE-HF): a randomized controlled trial. *The Lancet*. 2021;398:991-1001

Abbott
6101 Stoneridge Dr., Pleasanton, CA 94588 USA, Tel: 1925 847 8600
Cardiovascular.Abbott/CardioMEMS

Rx Only

Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use.

CardioMEMS™ HF System Indications and Usage: The CardioMEMS™ HF System is indicated for wirelessly measuring and monitoring pulmonary artery pressure and heart rate in NYHA Class II or III heart failure patients who either have been hospitalized for heart failure in the previous year and/or have elevated natriuretic peptides. The hemodynamic data are used by physicians for heart failure management with the goal of controlling pulmonary artery pressures and reducing heart failure hospitalizations.

CardioMEMS™ HF System Contraindications: The CardioMEMS HF System is contraindicated for patients with an inability to take dual antiplatelet or anticoagulants for one month post implant.

CardioMEMS™ HF System Potential Adverse Events: Potential adverse events associated with the implantation procedure include, but are not limited to, the following: air embolism, allergic reaction, infection, delayed wound healing, arrhythmias, bleeding, hemoptysis, hematoma, nausea, cerebrovascular accident, thrombus, cardiovascular injury, myocardial infarction, death, embolization, thermal burn, cardiac perforation, pneumothorax, thoracic duct injury and hemothorax.

MAT-2601122 v1.0 | Item approved for U.S. use only.